cytomegalovirus glycoprotein B + MF59

The cytomegalovirus glycoprotein B + MF59 is a recombinant subunit vaccine candidate designed to prevent human cytomegalovirus (HCMV) infection. It consists of a truncated, recombinant version of the HCMV envelope glycoprotein B (gB), which is a key protein for viral entry and a primary target for neutralizing antibodies. The vaccine is formulated with the MF59 adjuvant, a squalene-based oil-in-water emulsion that enhances the magnitude and breadth of the immune response by stimulating the recruitment and activation of antigen-presenting cells at the injection site. In Phase 2 clinical trials, the vaccine demonstrated approximately 50% efficacy in preventing CMV infection among postpartum women and adolescent girls, and showed potential in reducing viral load in solid organ transplant recipients. However, it did not progress to Phase 3, largely because it failed to induce high levels of neutralizing antibodies against the pentameric complex required for viral entry into epithelial and endothelial cells.

Other names

CMV gB/MF59 vaccineRecombinant CMV gB vaccine with MF59 adjuvantCMV-gB Vaccine